<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826471</url>
  </required_header>
  <id_info>
    <org_study_id>ReGl/20/Dec-Der/001</org_study_id>
    <nct_id>NCT04826471</nct_id>
  </id_info>
  <brief_title>Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam</brief_title>
  <official_title>Multicenter, Open Label, Uncontrolled Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam in the Management of Some Dermatitis in the Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Relife S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Relife S.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of this open label clinical trial is to evaluate and confirm the performance of&#xD;
      DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the&#xD;
      symptomatology. The disease severity will be clinically measured through the Investigator&#xD;
      Global Assessment (IGA) after 28 days of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The scope of this open label clinical trial is to evaluate and confirm the performance of&#xD;
      DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the&#xD;
      symptomatology. The product will be applied for 42 days of treatment, 2 times per day into&#xD;
      the face.&#xD;
&#xD;
      The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety&#xD;
      of the product&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, open label, uncontrolled, single arm, post-market clinical folow-up study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate and confirm the performance of the DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the symptomatology.</measure>
    <time_frame>28 days of treatment</time_frame>
    <description>The disease severity will be clinically measured through the Investigator Global Assessment (IGA) for dermatitis after 28 days of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to evaluate the performance of the DermoRelizema ecofoam</measure>
    <time_frame>after 14 and 42 days of treatment</time_frame>
    <description>to evaluate the performance of the DermoRelizema ecofoam in the improvement of dermatitis severity (IGA) after 14 and 42 days of treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate the eczema</measure>
    <time_frame>to 14, 28 and 42 days of treatment</time_frame>
    <description>to evaluate the eczema improvement through the EASI (Eczema Area and Severity Index) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate the improvement in itching, burning, pain and pruritus at visits</measure>
    <time_frame>to 14, 28 and 42 days of treatment</time_frame>
    <description>to evaluate the improvement in pain and pruritus at visits, as reported by the subject at visits by VAS (Visual Analogue Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate improvement in the Quality of Life (QoL) of the subject related to his/her dermatitis,</measure>
    <time_frame>to 14, 28 and 42 days of treatment</time_frame>
    <description>to evaluate improvement in the Quality of Life (QoL) of the subject related to his/her dermatitis, through the DLQI (Dermatology Life Quality Index) questionnaire;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate the subject's adherence to treatment.</measure>
    <time_frame>to 14, 28 and 42 days of treatment</time_frame>
    <description>to evaluate the subject's adherence to treatment, reported on the subject's diary and the product accountability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate the subject's and Investigator's global evaluation of performance of DermoRelizema ecofoam</measure>
    <time_frame>at the end of the study ( day 42)</time_frame>
    <description>to evaluate the subject's and Investigator's global evaluation of performance of DermoRelizema ecofoam by means of a 7-items scale (where 1 = very much improved, 2 = improved, 3 = minimally improved, 4&#xD;
= no change, 5 = minimally worse, 6 = worse, 7 = very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate the subject's overall acceptability of the treatment</measure>
    <time_frame>at the end of the study ( day 42)</time_frame>
    <description>to evaluate the subject's overall acceptability of the treatment (which takes into account pleasant or unpleasant feeling with the product and the ease of use), performed by means of a 5-item scale (where 1 = very much satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very much dissatisfied)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dermatitis</condition>
  <arm_group>
    <arm_group_label>DermoRelizema ecofoam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DermoReizema ecofoam for 42 days, 2 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DermoRelizema ecofoam</intervention_name>
    <description>DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration</description>
    <arm_group_label>DermoRelizema ecofoam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's written informed consent obtained prior to any studyrelated procedures;&#xD;
&#xD;
          2. Generally healthy male and female aged â‰¥ 18 years;&#xD;
&#xD;
          3. Presence of dermatitis of any typology, including atopic dermatitis (AD), irritant&#xD;
             contact dermatitis (ICD) or allergic contact dermatitis (ACD), of mild-moderate&#xD;
             severity:&#xD;
&#xD;
               -  IGA score 2 (=mild) or 3 (=moderate);&#xD;
&#xD;
          4. Dermatitis affecting one or more body areas (face, legs, arms, etc.);&#xD;
&#xD;
          5. Subjects with cooperative attitude, able to comprehend the full nature and the purpose&#xD;
             of the investigation, including possible risks and side effects, and able to comply&#xD;
             with the requirements of the entire investigation (including ability to attend the&#xD;
             planned visits according to the time limits), based on Investigator's judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe dermatitis at inclusion;&#xD;
&#xD;
          2. Pregnant and breastfeeding women;&#xD;
&#xD;
          3. Concomitant other skin disorders including skin infections;&#xD;
&#xD;
          4. Currently or previously diagnosed or treated (chemotherapy and/or radiotherapy) for&#xD;
             cancer in the past 5 years;&#xD;
&#xD;
          5. History of previous skin cancer (history of non-metastatic squamous or basal cell&#xD;
             carcinoma of the skin is allowed);&#xD;
&#xD;
          6. Active infections or use of antibiotics in the past 7 days;&#xD;
&#xD;
          7. Diabetic subjects;&#xD;
&#xD;
          8. History of congenital or acquired immunodepression;&#xD;
&#xD;
          9. Immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, any&#xD;
             typology of lupus, rheumatoid arthritis) which could place the subject at risk or&#xD;
             interfere with study results;&#xD;
&#xD;
         10. Use of any topic medication for dermatitis in the past 14 days;&#xD;
&#xD;
         11. Use of any topic product for dermatitis in the 2 days before study treatment start;&#xD;
&#xD;
         12. Any systemic treatment or procedure that could influence dermatitis activity within&#xD;
             the past 30 days (or 5 half-lives);&#xD;
&#xD;
         13. Use of any corticosteroids, immunosuppressant drugs or immunotherapy within the past&#xD;
             30 days (or 5 half-lives);&#xD;
&#xD;
         14. Use of oral antihistamines and antidepressants in the past 30 days;&#xD;
&#xD;
         15. Subjects with any other clinically significant or unstable concurrent disease or skin&#xD;
             condition or general condition that, in the Investigator's opinion, might interfere&#xD;
             with the study evaluations;&#xD;
&#xD;
         16. Allergy, sensitivity or intolerance to the components of the investigational device&#xD;
             formulations ingredients;&#xD;
&#xD;
         17. Concomitant or previous participation in other interventional clinical study in the&#xD;
             past 3 months;&#xD;
&#xD;
         18. Subjects planning sun exposure or tanning booths or UV sources throughout the course&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriella Fabbrocini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale &quot;Federico II&quot; Napoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriella Fabbrocini, MD</last_name>
    <phone>0817462448</phone>
    <email>gafabbro@unina.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <state>Italia</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Fabbrocini, MD</last_name>
      <phone>0817462448</phone>
      <email>gafabbro@unina.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ecofoam</keyword>
  <keyword>DermoRelizema ecofoam</keyword>
  <keyword>dermatitis treatment</keyword>
  <keyword>mild moderate dermatitis</keyword>
  <keyword>atopic dermatitis</keyword>
  <keyword>contact dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

